|By PR Newswire||
|February 18, 2014 04:20 PM EST||
CENTENNIAL, Colo., Feb. 18, 2014 /PRNewswire-USNewswire/ -- Peter Stevens, the Vice President of Research & Development and Marketing at AlloSource (allosource.org), one of the nation's largest non-profit providers of skin, bone and soft tissue allografts for use in surgical procedures, and the world's largest processor of cellular bone allografts, has been named to the Advisory Board for the University of Denver's Professional Sciences Master's Program in Biomedical Sciences.
The Professional Sciences Master's Program in Biomedical Sciences is a new program for the University of Denver that will begin in the fall of 2014. The rigorous one-year program will offer academic training and professional skills to prepare students for careers in the health sciences and biomedical sciences fields. Students will also gain an awareness of the current issues facing the health and biomedical science industries.
"I look forward to using my experience from AlloSource and beyond to provide input to help students translate their research ideas into real world solutions that can be used to improve the lives of patients," Stevens said. "Education has been paramount to my career and I am grateful for the opportunity to assist these students with their academic endeavors."
Stevens will provide valuable input on the program's curriculum, as well as advice on what academic and professional skills will best serve both the students and potential employers hiring in the biomedical industry. With more than 30 years of experience in the medical device industry, Stevens has worked with a range of medical device companies and provided strategic input, market analysis, and practical advice for implementation and commercial success. His experience has spanned the globe; he has worked in Europe, the United States, Asia and Latin America.
Stevens has previously served on advisory boards with Virginia Commonwealth University, the University of Texas at Dallas and the Parker H. Petit Institute for Bioengineering and Bioscience at Emory University, giving advice on course content, technology transfer and research direction.
AlloSource is a non-profit company that offers more than 200 types of precise bone, skin, soft-tissue and custom-machined allografts for use in an array of life-saving and life-enhancing medical procedures. As the world's leader in fresh cartilage tissue used for joint repair and skin allografts to heal severe burns, AlloSource has grown into one of the largest tissue networks in the country with more than 400 employees. It is the world's largest processor of cellular bone allografts and delivers unparalleled expertise and customer service to its growing network of surgeons, partners and the country's most reputable organ procurement organizations. As one of the leading innovators in maximizing tissue donation with the goal of offering optimal solutions for healthcare providers and their patients, AlloSource is recognized by the medical community for its ability to process and provide high quality tissue. The company is accredited by the American Association of Tissue Banks and is headquartered in Centennial, CO. For more information, please visit allosource.org or our educational website, allograftpossibilities.org.
720. 382. 2766
Predictive analytics tools monitor, report, and troubleshoot in order to make proactive decisions about the health, performance, and utilization of storage. Most enterprises combine cloud and on-premise storage, resulting in blended environments of physical, virtual, cloud, and other platforms, which justifies more sophisticated storage analytics. In his session at 18th Cloud Expo, Peter McCallum, Vice President of Datacenter Solutions at FalconStor, will discuss using predictive analytics to ...
Feb. 13, 2016 06:45 AM EST Reads: 417
Feb. 13, 2016 05:00 AM EST
Feb. 13, 2016 04:45 AM EST Reads: 465
Feb. 13, 2016 03:45 AM EST Reads: 242
Feb. 13, 2016 03:00 AM EST Reads: 463
Feb. 13, 2016 02:30 AM EST Reads: 368
Feb. 13, 2016 02:30 AM EST Reads: 371
Feb. 13, 2016 12:45 AM EST Reads: 277
Feb. 12, 2016 10:00 PM EST Reads: 245
Feb. 12, 2016 09:45 PM EST Reads: 386
Feb. 12, 2016 09:00 PM EST Reads: 136
Feb. 12, 2016 06:00 PM EST Reads: 404
Feb. 12, 2016 06:00 PM EST
Feb. 12, 2016 04:45 PM EST
Feb. 12, 2016 04:30 PM EST